ReviewExpert opinion on investigational drugs2011
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.
Review in Expert opinion on investigational drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Guideline
- New Horizons of Biomarkers in Metastatic Thyroid Cancer.Journal of Cancer · 2025Review
- Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.Nature reviews. Endocrinology · 2020Review
- hsa-miR-195-5p inhibits cell proliferation of human thyroid carcinoma cells via modulation of p21/cyclin D1 axis.Translational cancer research · 2020Article
- Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.Frontiers in oncology · 2020Article
- MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer.Oncotarget · 2019Article
- Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- FOXD3 regulates anaplastic thyroid cancer progression.Oncotarget · 2017Article
- Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Nature reviews. Clinical oncology · 2016Review
- Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.Endocrine · 2016Review
- RET Kinase Inhibitors May Treat Cancer and Gastrointestinal Disorders.ACS medicinal chemistry letters · 2015Article
- Advances in thyroid cancer treatment: latest evidence and clinical potential.Therapeutic advances in medical oncology · 2015Review
- Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.The Journal of clinical endocrinology and metabolism · 2015Review
- A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.Thyroid : official journal of the American Thyroid Association · 2014Article
- Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.The Journal of clinical endocrinology and metabolism · 2014Article
- Update: the status of clinical trials with kinase inhibitors in thyroid cancer.The Journal of clinical endocrinology and metabolism · 2014Review
- Curcumin Enhances Docetaxel-Induced Apoptosis of 8505C Anaplastic Thyroid Carcinoma Cells.Endocrinology and metabolism (Seoul, Korea) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options. AREAS COVERED: Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers. EXPERT OPINION: Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.